Archive: Company News
Company News: Omnix Medical Wins €10.8M in EIC Accelerator Funding
— Novel class of anti-infectives fighting hospital-associated infections and multi-drug resistant bacteria
— Lead program OMN6 to be advanced to proof-of-concept in humans
— Antonius Schuh appointed as Chairman of the Board of Directors
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme. The award will speed up Omnix Medical’s groundbreaking work in the fight against antimicrobial resistance based on peptides used by insects to fight bacteria.
Company News: T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer
T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
Allero Therapeutics Expands Management Team with Two Key Hires
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management team.
As of December 1, 2020, Steven Glazer has joined the Company as Chief Medical Officer and Christophe Saillez as Vice President Regulatory Affairs.
Company News: First-In-Human Heart Failure Data of Cardior Pharmaceuticals´ Novel miRNA Antisense Therapy Presented at the 17th Global Cardiovascular Clinical Trialists Forum
— Excellent safety and tolerability of first-in-class compound CDR132L
— Novel mode of action confirmed by data on cardiac function and biomarkers
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, today announced that its Chief Scientific Officer Thomas Thum, MD, PhD, has presented clinical data on the Company´s lead compound CDR131L at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) on December 7, 2020.